PDS Biotech rises as interim cancer trial data shows survival benefits
28/12/2022 15:33
** Shares of cancer therapy developer PDS Biotechnology Corp
PDSB.O up 7.3% at $9.88 in morning trade
** Company announces updated interim data from its mid-stage
study of a combination therapy in advanced human
papillomavirus-related cancers
** PDSB reports median overall survival of 21 months vs
historical data of 3-4 months in patients with refractory cancer
** Company reports 63% response rate in patients with
refractory cancer vs less than 10% in current approaches
** Safety data remains consistent with October update - PDSB
** Including session's gains, stock up ~22% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing